[Skip to Content]
[Skip to Content Landing]
Views 95
Citations 0
Comment & Response
February 2016

Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses

Author Affiliations
  • 1Department of Public Health, Erasmus MC Rotterdam, Rotterdam, the Netherlands

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Oncol. 2016;2(2):277-278. doi:10.1001/jamaoncol.2015.4457

To the Editor Goffin et al1 provide model-based estimates on the cost-effectiveness of lung cancer screening in Canada. However, their analyses warrant additional clarification.

The authors state that they use general mortality rates. However, mortality differs substantially across different smoking behaviors.2 Therefore, the authors do not appropriately estimate the life-years and quality-adjusted life-years (QALYs) gained by screening.